ISPOR - Economic Evaluation of Axitinib for Second Line Treatment in Adult Patients with Advanced Renal Cell Carcinoma – the Portuguese Case

Full Text

Economic Evaluation of Axitinib for Second Line Treatment in Adult Patients with Advanced Renal Cell Carcinoma – the Portuguese Case

Abstract

Authors

L.S. Miguel R. Luz

Back to Volume 17, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now